Table 4.
Association between immune cell counts ratio, inflammatory-related CpGs and overall survival time among cases from cohorts only (n = 342)
| Multivariate HR (95% CI) US cohorts |
|
|---|---|
| CD4/CD8 Ratioa | |
| Q1 [0.27, 1.45) | ref. |
| Q2 [1.48, 2.38) | 1.08 (0.82, 1.41) |
| Q3 [2.39, 32.33] | 0.96 (0.74, 1.26) |
| p for continuous = 0.79 | |
| Neutrophil/Lymphocyte Ratioa | |
| Q1 [0.54, 1.49) | ref. |
| Q2 [1.49, 2.09) | 0.88 (0.68, 1.16) |
| Q3 [2.09, 8.63] | 1.08 (0.83, 1.41) |
| p for continuous = 0.57 | |
| B cell /Lymphocyte Ratioa | |
| Q1 [0.01, 0.13) | ref. |
| Q2 [0.13, 0.17) | 1.13 (0.87, 1.48) |
| Q3 [0.17, 0.43] | 1.14 (0.86, 1.51) |
| p for continuous = 0.37 | |
| T cell /Lymphocyte Ratioa | |
| Q1 [0.38, 0.60) | ref. |
| Q2 [0.61, 0.68) | 0.85 (0.65, 1.10) |
| Q3 [0.68, 0.88] | 0.99 (0.76, 1.30) |
| p for continuous = 0.95 | |
| cg00159243a, b | |
| Q1 [0.24, 0.33) | ref. |
| Q2 [0.33, 0.37) | 1.29 (0.96, 1.74) |
| Q3 [0.37, 0.45] | 1.42 (1.00, 2.02) |
| p for continuous = 0.049 | |
| cg03957124a, b | |
| Q1 [0.40, 0.53) | ref. |
| Q2 [0.53, 0.58) | 0.81 (0.60, 1.08) |
| Q3 [0.58, 0.69] | 0.63 (0.42, 0.93) |
| p for continuous = 0.02 | |
| cg12785694a, b | |
| Q1 [0.07, 0.15) | ref. |
| Q2 [0.15, 0.20) | 1.00 (0.75, 1.34) |
| Q3 [0.20, 0.42] | 1.42 (1.02, 1.99) |
| p for continuous = 0.04 | |
| cg18181703a, b | |
| Q1 [0.34, 0.45) | ref. |
| Q2 [0.45, 0.50) | 0.92 (0.69, 1.22) |
| Q3 [0.50, 0.58] | 0.72 (0.54, 0.96) |
| p for continuous = 0.03 | |
| cg25325512a, b | |
| Q1 [0.25, 0.37) | ref. |
| Q2 [0.37, 0.42) | 0.90 (0.68, 1.18) |
| Q3 [0.42, 0.55] | 0.66 (0.49, 0.88) |
| p for continuous = 0.004 | |
| cg26804423a, b | |
| Q1 [0.61, 0.70) | ref. |
| Q2 [0.70, 0.74) | 1.13 (0.84, 1.52) |
| Q3 [0.74, 0.83] | 1.50 (1.04, 2.17) |
| p for continuous = 0.03 |
a
Adjusted for age, date of blood draw, time between blood draw and cancer diagnosis, smoking, and cohorts for combined analyses.
b
Further adjusted for cell proportions.